Ascorbic Acid for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 15 Feb 2018: Trial registered, NCT03433781
  2. 1 May 2018: Trial started, NCT03433781

The trials

NCT02877277: Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study

State
Completed
Phase
No phase
People
20 taking part
Started
8 Aug 2016
Primary completion
29 May 2017
Arms
Vitamin C
Results
None posted
  1. 8 Aug 2016: Trial started
  2. 24 Aug 2016: Trial registered
  3. 29 May 2017: Trial completed

NCT03433781: A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

State
Completed
Phase
Phase 1 and Phase 2
People
4 taking part
Started
1 May 2018
Primary completion
6 Nov 2022
Arms
Vitamin C 50 g, Vitamin C 75 g, Vitamin C 100 g
Results
Posted on the registry
  1. 15 Feb 2018: Trial registered
  2. 1 May 2018: Trial started
  3. 16 May 2023: Trial completed
  4. 27 Mar 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Also known as Ascoltin, Ascor, Ascorbicap, High-dose ascorbate, Vitamin C.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.